翻修指征与翻修全髋关节置换术后早期死亡率相关:一项基于人群的研究
该研究纳入1997至2023年间单中心6946例患者共8667例翻修全髋关节置换术(R-THA),评估术后30天和90天死亡率。结果显示30天死亡率为0.5%、90天为0.9%,翻修范围与死亡率无关,但假体周围骨折(PPFx)和假体周围关节感染(PJI)翻修者的早期死亡率显著高于无菌性松动者,且高于一般人群预期。
要点
- R-THA术后30天死亡率为0.5%,90天死亡率为0.9%。
- PPFx和PJI翻修者90天死亡率分别为2.6%和1.4%,显著高于无菌性松动的0.4%。
- 翻修范围(单组件、双组件、模块化组件交换)与死亡率无关。
核心结论
- R-THA术后30天和90天死亡率较低,且与翻修范围无关,但受翻修指征强烈影响。
- 因PPFx或PJI行翻修者相比无菌性松动者,90天内死亡风险升高约3至4倍。
- 因PPFx或PJI行翻修者相比年龄和性别匹配的美国一般人群,早期死亡率升高。
研究设计与样本
- 基于单中心1997至2023年6946例患者共8667例R-THA的回顾性人群研究。
- 患者平均年龄66岁,平均体重指数30,53%为女性。
- 采用Kaplan-Meier分析评估30天和90天死亡率,调整Cox模型识别危险因素,并以标准化死亡比(SMR)与预期死亡数比较。
主要发现
- 30天死亡38例(0.5%),90天死亡75例(0.9%)。
- 90天未调整死亡率:PPFx为2.6%,PJI为1.4%,脱位为0.9%,无菌性松动为0.4%。
- 相比无菌性松动,PPFx翻修的调整30天死亡风险比(HR)为5.37、90天HR为3.96;PJI翻修的调整30天HR为3.16、90天HR为2.95(均P<0.01)。
- 翻修范围与死亡率无关(P>0.05)。
- R-THA总体30天死亡率高于一般人群(SMR=1.77;P=0.002),主要由PPFx(30天SMR=3.67;90天SMR=2.61)和PJI(30天SMR=3.18;90天SMR=2.0)驱动(均P<0.001)。
关键数值与推荐
- 翻修指征分布:无菌性松动37%、PJI 15%、脱位14%、PPFx 11%。
- 翻修类型分布:单组件交换49%、双组件交换30%、模块化组件交换21%。
- 证据等级为III级。
临床怎么用
- 对因PPFx或PJI行R-THA的患者应加强围手术期风险评估与术后早期监测。
- 翻修范围本身不增加早期死亡风险,决策时可更多关注翻修指征而非范围。
局限性
- 研究为单中心回顾性设计,证据等级为III级。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Revision total hip arthroplasty (R-THA) is associated with increased complexity and potential for early postoperative complications, including mortality. This study evaluated 30- and 90-day mortality after R-THA. METHODS: We identified 6,946 patients undergoing 8,667 R-THA at a single institution between 1997 and 2023. Their mean age was 66 years, and they had a mean body mass index of 30, and 53% were women. Indications for R-THA included aseptic loosening (37%), periprosthetic joint infection (PJI) (15%), dislocation (14%), and periprosthetic fracture (PPFx) (11%). Revisions included single-component (49%), both-component (30%), and modular-component exchanges (21%). Mortality at 30 and 90 days was assessed using Kaplan-Meier analysis. Adjusted Cox models identified the risk factors. The observed number of deaths was compared with the expected number of deaths using standardized mortality ratios (SMR). RESULTS: The 30- and 90-day mortalities were 0.5% (n = 38) and 0.9% (n = 75), respectively. Unadjusted mortality rates at 90 days were 2.6% for PPfx, 1.4% for PJI, 0.9% for dislocation, and 0.4% for aseptic loosening. Compared with aseptic loosening, revision for PPFx and PJI had increased adjusted 30-day mortality (hazard ratio = 5.37 and 3.16) and 90-day mortality (hazard ratio = 3.96 and 2.95; all P < 0.01). The extent of revision was not associated with mortality (P > 0.05). Overall, compared with individuals in the general population, 30-day mortality among patients undergoing R-THA was higher (SMR = 1.77; P = 0.002), and this is primarily driven by a higher 30- and 90-day mortality seen in those undergoing revision for PPFx (30-day SMR = 3.67; 90-day SMR = 2.61) or PJI (30-day SMR = 3.18; 90-day SMR = 2.0 [all P < 0.001]). CONCLUSIONS: Revision THA carries a low 30- and 90-day mortality risk that is not associated with the extent of revision but is strongly impacted by the indication for revision. Patients revised for PPfx and PJI face a 3- and 4-fold higher risk of mortality within 90 days compared to aseptic loosening and demonstrate increased early mortality when compared with age- and sex-matched United States population expectations. LEVEL OF EVIDENCE: III.
引用
- Restrepo DJ, Gonzalez-Bravo AE, Guarin Perez SF, et al. Revision Indication is Associated With Early Mortality After Revision Total Hip Arthroplasty: A Population-Based Study. J Arthroplasty. 2026. PMID: 42767523. doi:10.1016/j.arth.2026.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。